PAR 2.38% 20.5¢ paradigm biopharmaceuticals limited..

research reports and media, page-3332

  1. 3,799 Posts.
    lightbulb Created with Sketch. 1562
    You can’t blame BP for looking after themselves. It’s up to our CEO and board to protect shareholder interest.

    While I was disappointed with how our board went about it, I certainly didn’t miss the opportunity that was presented and gorged myself on market that by the time it came to taking up my allocation, I was full. The fact there was free floating shares said to me there were too many issued at too deep a discount. That’s on our board.

    One thing I’m glad didn’t happen was attaching options. This has become an ugly trend on the ASX and is only good if loyal shareholders are included. In fact attaching options should only ever be included for current shareholders and never for these types of raises. The dilution becomes to great to be of any use.

    Now as far as suggestion of share price, I came out and said that $355 is a target price I have in the future and his theory fits in roughly with mine. He hasn’t convinced me through power of suggestion, it was my independent figure based on my own research. The fact that his “suggestions” are close to my own research, is only coincidence or they have a similar thought process.

    By all means question everything, I know I do, and by all means throw your barbs in the right directions to keep people on their toes, once again I know I do, but there is also times for positivity and yesterday was one of those days.


 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.